Detailly, the incidence of MET amplification in NSCLC patients resistant to third-generation EGFR-TKIs increased from 5-22% to 5-50% compared to the patients’ resistance to the first/second-generation EGFR-TKIs (16). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.